Researchers at Biodol Therapeutics SAS, Centre National de la Recherche Scientifique, INSERM and Université de Strasbourg have divulged new n-heteroarylbenzamide derivatives acting as FLT3 (FLK2/STK1) inhibitors and reported to be useful for the treatment of pain.

Nimbus Clio Inc. has identified E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Hanmi Holdings Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

Buddhist Tzu Chi General Hospital has described oligopeptides isolated from turtle gum reported to be useful for the treatment of bone disorders.

Pfizer Inc. has divulged 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17- β-HSD 13) inhibitors and/or degraders reported to be useful for the treatment of hepatocellular carcinoma, biliary cirrhosis, hepatitis B and hepatitis C viral infections, alcoholic and nonalcoholic fatty liver disease, among others.

Ryvu Therapeutics SA has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Jeil Pharmaceutical Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.

Kurome Therapeutics Inc. along with the Cincinnati Children’s Hospital Medical Center and U.S. Department of Health and Human Services have patented interleukin-1 receptor-associated kinase (IRAK) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Novorex Inc. has patented protein ENL (MLLT1; YEATS1) and protein AF-9 (MLLT3; AF9) inhibitors reported to be useful for the treatment of cancer.